Document ID: EPA-HQ-OPP-2004-0099-0004
Agency: epa
Document Type: Supporting & Related Material
Title: 
Posted Date: 2004-04-20T04:00Z

Page
1
of
9
April
19,
2004
FIFRA
SCIENTIFIC
ADVISORY
PANEL
(
SAP)
OPEN
MEETING
MAY
4­
6,
2004
FIFRA
SAP
WEB
SITE
http://
www.
epa.
gov/
scipoly/
sap/
OPP
Docket
Telephone:
(
703)
305­
5805
Docket
Number:
OPP­
2004­
0099
CONSULTATION
ON
DERMAL
SENSITIZATION
ISSUES
FOR
EXPOSURES
TO
PESTICIDES
PANEL
MEMBER
BIOGRAPHICAL
SKETCHES
Gary
R.
Burleson,
Ph.
D.

Dr.
Burleson
received
his
Ph.
D.
from
the
Medical
College
of
Wisconsin
with
post
doctoral
training
at
the
University
of
Notre
Dame.
He
has
over
20
years
professional
experience
in
academia,
clinical,
contract
research,
government
research
and
the
pharmaceutical
industry.
This
experience
includes
academic
appointments
and
affiliations
at
the
University
of
Notre
Dame,
North
Carolina
State
University,
the
University
of
North
Carolina
at
Chapel
Hill,
and
New
York
University;
clinical
experience
at
Milwaukee
County
General
Hospital;
contract
research
organization
experience,
government
regulatory
experience
at
the
U.
S.
Environmental
Protection
Agency
(
USEPA);
and
pharmaceutical
experience
in
drug
discovery
at
Procter
&
Gamble.
Dr.
Burleson
has
scientific
expertise
in
the
following
broad
areas:
Microbiology,
Immunology,
Virology,
Clinical
Microbiology,
Viral
Pathology,
Pulmonary
Immunology,
Tumor
Metastasis,
Immunomodulation,
Inflammation,
Immunotoxicology,
Hypersensitivity,
and
Computer
Disease
Modeling.
Page
2
of
9
Ih
Chu,
Ph.
D.

Dr.
Chu
obtained
his
Ph.
D.
in
pharmacology
in
1973.
Following
2
year
post­
doctoral
training,
he
joined
Health
Canada
as
research
scientist.
As
Head
of
Systemic
Toxicology
and
Pharmacokinetics
section,
he
directs
research
on
pharmacokinetics,
biochemical
toxicology,
neurotoxicology,
endocrine
disputers,
reproductive
and
systemic
effects
of
persistent
environmental
pollutants.
The
section
also
engages
in
developing
molecular
biomarkers
and
alternative
methods
for
toxicity
and
exposure
assessments.

Dr.
Chu's
current
research
focuses
on
the
interactive
and
mixture
effects
of
environmental
pollutants,
and
toxicology
studies
of
oxygenated
and
renewal
fuels.
He
leads
projects
funded
by
the
Program
on
Energy
Research
and
Development
and
Northern
Contaminants
Program
to
investigate
toxicity
of
advanced
transportation
fuels
and
the
developmental
neurotoxicity
of
the
mixtures
of
persistent
organic
pollutants.
He
has
authored
and
co­
authored
some
150
research
papers
in
peer
reviewed
journals,
book
chapters
and
reviews
in
toxicology.
He
also
serves
on
a
number
of
expert
panels
and
task
groups
reviewing
test
guidelines
and
test
methods.
Research
from
his
group
has
strongly
impacted
the
development
of
test
guidelines
and
regulatory
requirements
for
toxic
chemicals.
Page
3
of
9
Peter
Griem,
Ph.
D.

Dr.
Peter
Griem
is
currently
a
Toxicologist
with
the
fine
and
specialty
chemicals
company
Clariant
(
Muttenz,
Switzerland)
working
at
the
German
subsidiary
Clariant
GmbH
in
Sulzbach
Germany.
His
primary
areas
of
interest
include
skin
sensitization
and
how
this
endpoint
can
be
addressed
in
regulatory
toxicology.
Dr.
Griem
holds
a
Diploma
degree
in
Biochemistry
from
Tuebingen
University
(
Germany),
a
Ph.
D.
(
Dr.
rer.
nat)
in
Immunology/
Immunotoxicology
from
Duesseldorf
University
(
Germany)
and
a
Certification
as
Toxicologist
from
the
German
Society
for
Pharmacology
and
Toxicology
(
DGPT).
He
formerly
worked
with
a
toxicology
consultant
firm
and
a
cosmetics
company.
Page
4
of
9
A.
Wallace
Hayes,
PhD,
DABT,
FATS,
FIBiol,
FACFE,
ERT
Dr.
Hayes
is
a
toxicologist
with
over
30
years
of
experience.
He
has
written
over
200
peer
reviewed
publications
and
is
the
editor
of
the
textbook,
Principles
and
Methods
of
Toxicology,
the
international
Journal
of
Human
and
Experimental
Toxicology
and
a
co­
editor
of
the
Target
Organ
Toxicity
Series.
Dr.
Hayes
also
is
the
editor
of
the
Journal
of
Toxicology­
Cutaneous
and
Ocular
Toxicology.
Before
joining
Harvard
School
of
Public
Health
as
a
visiting
scientist,
Dr.
Hayes
was
Vice
President
of
Corporate
Product
Integrity
at
the
Gillette
Company,
where
he
had
management
responsibility
for
the
safety
evaluation
of
a
variety
of
consumer
products,
plant
safety,
environmental
stewardship,
and
quality
control.
Dr.
Hayes
is
an
adjunct
professor
at
Wake
Forest
University
School
of
Medicine,
the
University
of
Louisville
School
of
Medicine
and
the
School
of
Public
Health,
The
University
of
Massachusetts.
Dr.
Hayes
holds
degrees
from
Auburn
University
(
PhD
in
biochemistry,
M.
S.
in
physiology)
and
Emory
University.
Dr.
Hayes
was
a
NSF
predoctoral
fellow
at
Auburn
University,
a
NIH
postdoctoral
fellow
at
the
Vanderbilt
University
School
of
Medicine,
and
a
NATO
Senior
Scientist
at
the
Central
Veterinary
Laboratory,
Weybridge,
England.
Dr.
Hayes
currently
lectures
at
the
Harvard
School
of
Public
Health
and
at
Virginia
Polytechnic
and
State
University
and
in
the
Risk
Assessment
Summer
School
of
the
International
Union
of
Toxicology.
Dr.
Hayes
has
served
the
International
Union
of
Toxicology
as
the
editor
of
the
Proceedings
of
ICT
III
(
Developments
in
the
Science
and
Practice
of
Toxicology)
and
as
the
editor
of
the
Proceedings
of
the
5th
Congress
of
Toxicology
in
Developing
Countries
(
Toxicology
in
New
Century­
Opportunity
and
Challenge).
Dr.
Hayes
has
served
as
a
delegate
to
IUTOX
and
on
several
IUTOX
committees.
In
addition,
Dr.
Hayes
has
served
on
committees
for
the
National
Academy
of
Sciences,
the
National
Institution
of
Health,
and
the
Department
of
Defence.
Dr.
Hayes
is
a
diplomat
of
the
American
Board
of
Toxicology,
The
Academy
of
Toxicology
Sciences,
the
American
Board
of
Forensic
Medicine
and
the
American
Board
of
Forensic
Examiners.
He
is
a
Fellow
of
the
Academy
of
Toxicological
Sciences
and
Institute
of
Biological
Sciences
(
UK).
Dr.
Hayes
is
a
registered
toxicologist
in
the
European
Union
(
EUROTOX).
Page
5
of
9
Abigail
Jacobs,
Ph.
D.

Dr.
Jacobs
is
currently
Associate
Director
for
Pharmacology
/
Toxicology
for
Offices
of
Drug
Evaluation
(
ODEs)
4
and
5,
Center
for
Drug
Evaluation
(
CDER)/
FDA.
Dr.
Jacobs
received
a
B.
S.
in
chemistry
at
the
U.
of
Michigan,
Ann
Arbor,
and
a
Ph.
D.
in
biochemistry
at
the
U.
of
California,
Berkeley.
After
postdoctoral
work
in
immunochemistry
and
mast
cell
biochemistry,
she
became
a
toxicologist.
She
spent
numerous
years
working
for
the
National
Cancer
Institute/
National
Toxicology
Program
and
the
Division
of
AIDS,
NIAID,
NIH,
as
a
contractor
for
toxicologic
evaluation
before
joining
the
Division
of
Antiviral
Drug
Products,
CDER/
FDA,
as
a
toxicology
reviewer
in
1991.
From
1995­
2003,
Dr.
Jacobs
was
Pharmacology/
Toxicology
Supervisor
of
the
Division
of
Dermatologic
and
Dental
Drug
Products,
CDER/
FDA.
She
is
a
standing
member
of
the
CDER,
FDA,
Executive
Carcinogenicity
Assessment
Committee,
is
chair
of
a
number
of
CDER,
FDA,
Pharm/
Tox
Coordinating
Committee
working
groups,
and
represents
CDER
on
ICCVAM
(
Interagency
Committee
for
the
Validation
of
Alternative
Methods)
and
on
a
number
of
ICCVAM
working
groups.
She
also
represents
CDER/
FDA
on
OECD
pharm/
tox
issues.
Page
6
of
9
Nancy
Ann
Monteiro­
Riviere,
Ph.
D.

Dr.
Monteiro­
Riviere
is
a
Professor
of
Investigative
Dermatology
and
Toxicology
in
the
Center
for
Chemical
Toxicology
Research
and
Pharmacokinetics,
Department
of
Clinical
Sciences,
College
of
Veterinary
Medicine,
North
Carolina
State
University
(
NCSU)
in
Raleigh
NC.
She
received
her
B.
S.
in
Biology
(
cum
laude)
from
Stonehill
College
in
North
Easton,
MA
and
her
M.
S.
and
Ph.
D.
in
Anatomy
from
Purdue
University
in
West
Lafayette,
IN.
She
completed
post­
doctoral
training
in
Experimental
Pathology
/
Toxicology
at
the
Chemical
Industry
Institute
of
Toxicology
in
Research
Triangle
Park,
NC.
She
joined
the
faculty
at
NCSU
in
1984.
Dr.
Monteiro­
Riviere
is
also
a
Professor
in
the
NCSU/
UNC­
CH
Biomedical
Engineering
Faculty
as
well
as
being
a
Research
Adjunct
Professor
in
the
Department
of
Dermatology,
School
of
Medicine
at
the
University
of
North
Carolina
at
Chapel
Hill.
She
is
a
member
of
Sigma
Xi
and
Phi
Zeta
honor
societies.
Dr.
Monteiro­
Riviere
is
President
of
the
Dermatotoxicology
Specialty
Section,
and
past­
president
of
the
In
Vitro
Specialty
Section
of
the
Society
of
Toxicology.
She
presently
serves
on
the
NIH
Scientific
Advisory
Committee
on
Alternative
Toxicological
methods
(
SACATM),
the
Board
of
Publications
of
the
Society
of
Toxicology
and
Editorial
Boards
of
the
Journal
of
Applied
Toxicology,
Journal
of
Toxicology
­
Cutaneous
and
Ocular,
Toxicology
In
Vitro,
and
Toxicology
Mechanisms
and
Methods.
Dr.
Monteiro­
Riviere
has
published
more
than
145
publications,
holds
a
US
patent,
and
has
been
the
recipient
of
9
million
dollars
in
extramural
research
support
from
various
government
and
private
sources.
Her
current
research
interests
relate
to
chemical
absorption
and
mechanisms
of
chemical
irritation
to
skin.
Page
7
of
9
Richard
C.
Pleus,
Ph.
D.

Dr.
Pleus
is
Director
and
a
toxicologist
of
Intertox,
Inc.
He
is
an
expert
in
neurological
and
reproductive
toxicology
with
over
20
years
experience
assessing
the
risk
to
humans
exposed
to
chemical
and
biological
agents
via
food,
consumer
products,
therapeutic
agents,
and
the
environment.
He
has
a
proven
ability
to
communicate
risks
of
toxicants
to
a
variety
of
audiences
 
skillfully
facilitating
both
public
forums
and
industry
meetings,
in
litigation
support,
on
expert
panels,
and
as
an
expert
witness.
His
clients
include
industry,
citizen
groups,
and
governmental
agencies,
both
nationally
and
internationally.
He
continues
to
be
involved
in
research,
publications,
and
education.

Dr.
Pleus'
research
focuses
on
human
health
risk,
including
mode­
of­
action
studies
aimed
at
quantifying
exposure
to
critical
organ
systems,
with
particular
interest
in
human
and
laboratory
animal
nervous
system
development.
In
association
with
these
activities,
he
has
conducted
a
variety
of
human
health
risk
evaluations
of
exposures
to
chemical
and
biological
agents
in
air,
water,
food,
and
soil,
as
well
as
risk
evaluations
relating
to
consumer
products
and
therapeutic
agents.
His
work
is
focused
on
the
application
of
academic
research
results
to
protect
human
health
and
resolve
public
health
issues.
He
has
presented
the
results
of
his
research
at
national
and
international
meetings
in
Australia,
France,
South
Africa,
and
the
Czech
Republic.

Dr.
Pleus'
contribution
to
peer
reviewed
journals
and
books
include
his
work
regarding
perchlorate,
published
in
Environmental
Health
Perspectives
and
his
chapter
contribution,
Perchlorate
Regulation
and
Regulatory
Activity
(
Chapter
IX)
to
GFS
Chemicals
book
Perchloric
Acid
and
Perchlorate.
He
has
also
co­
authored
chapters
to
Biological
Risk
Engineering
Handbook:
Infection
Control
and
Decontamination
(
Lewis
Publishers),
chapter
4,
Toxicology,
and
chapter
5,
Risk
Assessment.

Dr.
Pleus
was
an
instructor
for
10
years
at
the
University
of
Minnesota
where
he
taught
human
science
classes
for
both
lower
and
upper
level
undergraduate
students.
In
addition,
he
taught
courses
in
physiological
psychology
and
psychopharmacology
for
Metropolitan
State
University.
He
periodically
serves
as
a
graduate
level
guest
lecturer
in
toxicology
at
the
School
of
Public
Health
at
the
University
of
Washington.
He
is
an
adjunct
Associate
Professor
in
the
Department
of
Pharmacology
at
the
University
of
Nebraska
Medical
Center,
as
well
as
a
faculty
member
of
the
Center
for
Environmental
Toxicology
at
the
University
of
Nebraska.
He
is
an
elected
member
of
the
Delta
Omega
Honorary
Society
in
Public
Health.

Dr.
Pleus'
credentials
include
a
B.
S.
with
Honors
from
Michigan
State
University,
an
M.
S.
in
Environmental
Health,
a
Ph.
D.
in
Environmental
Toxicology
from
the
University
of
Minnesota,
and
postdoctoral
research
in
neuropharmacology
at
the
University
of
Nebraska
Medical
Center.
Page
8
of
9
Paul
David
Siegel,
Ph.
D.,
M.
S.
P.
H.

Dr.
Siegel
is
Team
Leader­
Bioorganic
Chemistry/
Director
Scientist,
Research
Officer
and
the
National
Institute
for
Occupational
Safety
and
Health,
Analytical
Services
Branch/
Health
Effects
Laboratory
Division,
and
an
Adjunct
Associate
Professor
at
the
West
Virginia
University
School
of
Pharmacy,
Department
of
Basic
Pharmaceutical
Sciences.
Dr.
Siegel's
major
research
interests
are
in
the
area
of
immunological
sensitization
and
asthma
from
occupational
chemicals.
This
includes
modeling
of
exposure
routes
(
dermal
and
inhalation)
and
asthma­
like
responses,
biomarkers
of
sensitization
and
response,
and
exposure
characterization.
His
research
has
resulted
in
53
published
abstracts
and
50
peer­
reviewed
scientific
articles,
2
book
chapters,
9
internet
reports
and
10
invited
presentations.
He
is
chair
and/
or
serve
on
multiple
NIOSH
committees
and
has
taught
both
graduate
and
undergraduate
Pharmacy
courses,
co­
chaired
an
international
occupational
asthma
conference
and
am
an
ad
hoc
reviewer
for
several
scientific
journals.
He
has
a
B.
A.
in
Biology
from
the
University
of
Missouri,
Columbia,
MO,
a
MSPH
in
Environmental
Health
from
Tulane
University
and
a
Ph.
D.
in
Pharmacology/
Toxicology
from
Tulane
University.
Page
9
of
9
Alan
H.
Stern,
D.
P.
H.

Dr.
Stern
holds
a
Dr.
P.
H.
(
Doctor
of
Public
Health)
and
a
M.
P.
H.
in
Environmental
Sciences
from
Columbia
University.
He
is
the
Chief
of
the
Bureau
for
Risk
Analysis
in
the
Division
of
Science
and
Research
at
the
New
Jersey
Department
of
Environmental
Protection.
He
is
an
Adjunct
Associate
Professor
in
the
Division
of
Environmental
and
Occupational
Health
in
the
School
of
Public
Health,
University
of
Medicine
and
Dentistry
of
New
Jersey
(
UMDNJ),
and
an
Adjunct
Associate
Professor
in
the
Department
of
Environmental
and
Community
Medicine
,
UMDNJ­
Robert
Wood
Johnson
Medical
School.
He
specializes
in
toxicology,
human
health
risk
assessment
and
exposure
assessment.
Dr.
Stern's
primary
research
areas
include
risk
assessment
of
heavy
metals
including
mercury,
chromium
and
lead,
and
probabilistic
methods
in
health
risk
assessment.
He
regularly
teaches
graduate
classes
in
risk
assessment,
biological
monitoring
of
metals,
and
general
biological
monitoring
of
exposure.
Dr.
Stern
is
certified
in
toxicology
(
DABT)
by
the
American
Board
of
Toxicology.
He
has
served
on
a
number
of
peer
review
panels
for
the
US
EPA,
National
Academy
of
Sciences,
Toxicology
Excellence
for
Risk
Assessment
and
the
White
House
Office
of
Science
and
Technology
Policy
and
National
Institute
of
Environmental
Health
Sciences.